What the Real-World Data Shows About Omnipod 5

Omnipod 5 is a hybrid closed-loop automated insulin delivery (AID) system. That means it combines an insulin pump, a continuous glucose monitor, and a software algorithm that automatically adjusts insulin delivery based on real-time glucose readings. However, it's not fully automatic—users still make decisions about meals, activity, and their glucose targets.

The study grouped users by their average glucose target. These were observed choices, not randomly assigned settings.

A study published in 2024 analyzed data from 69,902 people using Omnipod 5 in the United States—the largest real-world look at how the system performs outside clinical trials. Researchers examined glucose targets users actually chose and the outcomes they achieved.

Users who set their average glucose target at 110 mg/dL achieved a median time in range (glucose between 70–180 mg/dL) of 68.8%. Those targeting 120 mg/dL reached 61.3%, and those targeting 130–150 mg/dL achieved 53.6%. Time below 70 mg/dL (low blood sugar) was minimal across all groups—less than 1.13% in the median user.

Younger users tended to use multiple or higher glucose targets, while adults using the lowest target (110 mg/dL) achieved time in range of 69.9%—notably higher than children and adolescents, who averaged 65.0%.

Comparisons across separate studies need caution: populations, methods and endpoints can differ. The observational study summarized here does not establish that one system is best for an individual.

Correction: the cited UK pregnancy trial evaluated a different automated insulin-delivery system. Its results must not be attributed to Omnipod 5.

Ongoing real-world registries are continuing to gather long-term safety and effectiveness data from Omnipod 5 users across age groups and in diverse clinical settings. This information helps clinicians understand how to optimize the system for individual people and identify any emerging patterns.

These group results do not prove that a setting change caused a better outcome. They cannot predict an individual result. Several authors were affiliated with Insulet, the manufacturer.

Origin: YouTube / She's Diabetic (Video report). Evidence: Video report, corroborated with 6 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Removed misleading pregnancy-study attribution, unsupported overall range and causal/comparative implications.